Klotho Neurosciences: A Promising Player in the Gene Therapy Space

Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer’s, and Parkinson’s disease, has announced its participation in the Biotech Showcase 2025 during the J.P. Morgan Healthcare Week in San Francisco. The company's presentation, scheduled for January 14, 2025, at 3:00 PM PT, will provide an opportunity for investors and healthcare professionals to learn more about Klotho Neurosciences' innovative approach to treating these devastating neurodegenerative disorders.

Klotho Neurosciences' proprietary cell and gene therapy platform is centered around the secreted form of the Klotho anti-aging gene ('s-KL'), which has shown promise in preclinical studies as a potential therapeutic agent for cognitive and behavioral impairments. The company has secured an exclusive worldwide license from Universitat Autònoma de Barcelona (UAB) and Institució Catalana de Recerca i Estudis Avançats (ICREA) in Spain, granting it the exclusive use of patents issued in the USA, Europe, and China for its innovative therapeutic approach using s-KL.

The company's pipeline consists of proprietary cell and gene therapy programs using DNA and RNA as therapeutics, as well as genomics-based diagnostics. Additionally, Klotho Neurosciences has other assets, including clinical-stage programs involving antibody biologics targeting cancer and autoimmune diseases, and drug delivery via a needle-free dry powder jet autoinjector called Nanoject.

Klotho Neurosciences' focus on neurodegenerative and age-related disorders aligns with significant market needs, as these conditions have high prevalence and unmet medical needs. The global market for neurodegenerative disease therapeutics is expected to reach $37.9 billion by 2027, growing at a CAGR of 8.5% during the forecast period (2020-2027) (Source: Grand View Research).



Klotho Neurosciences' patented s-KL/AAV.myo delivery system differentiates it from competitors in the gene therapy space by utilizing a novel approach to deliver the secreted form of the Klotho gene to target cells. The system's targeted delivery, efficient gene transfer, durable expression, and exclusive licensing provide a competitive advantage in the gene therapy market.

As Klotho Neurosciences continues to advance its clinical development pipeline, it faces potential risks and challenges, such as preclinical and clinical trial delays, regulatory approval uncertainty, financing and resource constraints, intellectual property and competition, patient recruitment and retention, and safety and efficacy concerns. However, by addressing these risks proactively and maintaining a strong focus on innovation and patient needs, Klotho Neurosciences has the potential to make a significant impact on the treatment landscape for neurodegenerative and age-related disorders.

In conclusion, Klotho Neurosciences' participation in the Biotech Showcase 2025 provides an opportunity for investors and healthcare professionals to learn more about the company's innovative approach to treating neurodegenerative disorders. With its proprietary cell and gene therapy platform, strong intellectual property position, and focus on high-unmet medical need areas, Klotho Neurosciences is well-positioned to make a significant impact on the biotechnology sector.